Genitourinary Cancer News

Standard eligibility criteria for pancreatic cancer clinical trials differentially exclude Black patients from participation, according to results a simulated screening process.

The FDA placed a clinical hold on a series of clinical trials that use Allogene Therapeutics’ AlloCAR T chimeric antigen receptor T-cell therapies, according to a press release from the manufacturer.

Removing race from estimated glomerular filtration rate equations could result in more Black patients being excluded from anticancer therapy, thus negatively affecting outcomes, according to study results published in The Lancet Oncology.

Indications for which cancer drugs receive accelerated approval often remain on drug labeling after confirmatory trials show no improvement in the primary efficacy endpoint, results of a retrospective, observational study showed.

Patients with solid tumor cancers sustained similar COVID-19 antibody levels as individuals without cancer 6 months after the second dose of the mRNA COVID-19 vaccine, according to study results published in Cancer Discovery.

The addition of berzosertib to cisplatin and gemcitabine did not extend PFS among patients with metastatic urothelial cancer, according to results of a randomized phase 2 trial.

The world of cancer cell therapy continues to evolve, and the next breakthrough may include T cells genetically modified to include T-cell receptors that recognize a wider array of tumor-associated antigens.

The world of cancer cell therapy continues to evolve, and the next breakthrough may include T cells genetically modified to include T-cell receptors that recognize a wider array of tumor-associated antigens.

The Prostate Cancer Foundation named Charles J. Ryan, MD, as its president and CEO.

To advance health equity, it is time to normalize the collection of sexual orientation and gender identity (SOGI) data in clinical practice and in health services research.